The intent of this process measure is to improve rates of guideline-concordant kidney health evaluation in patients with diabetes to more consistently identify and potentially treat or delay progression of CKD in this high-risk population. This public health issue is driven largely by the impact of diabetes-the most common comorbid risk factor for CKD (Saran et al., 2019 Bowe et al., 2018). CKD is the 9th leading cause of death in the US and is the fastest growing non-communicable disease in terms of in burden largely due to death (Hoerger et al., 2015 Bowe et al., 2018). Patients with CKD are readmitted to the hospital more frequently than those without diagnosed CKD (Saran et al., 2019). In the US from 2002-2016, the burden of CKD, defined as years of life lost, years living with disability, disability-adjusted life years, and deaths, outpaced changes in the burden of disease for other conditions (Bowe et al., 2018). ![]() Total Medicare spending in 2016 on both CKD and End-Stage Renal Disease (ESRD) was over $114 billion, comprising 23% of total Medicare fee-for-service spending overall with costs increasing exponentially with advancing CKD (Saran et al., 2019 Nichols et al., 2020). Currently, 37 million American adults have CKD and millions of others are at increased risk (National Kidney Foundation, 2019), with an estimated population prevalence growing to nearly 17% among Americans aged 30 years and older by the year 2030 (Saran et al., 2019 Hoerger et al., 2015). Please refer to the QDM page for more information on the QDM.Ĭhronic Kidney Disease (CKD) is a major driver of morbidity, mortality and high healthcare costs in the United States. This version of the eCQM uses QDM version 5.6. This measure does not preclude or discourage the use of regular laboratory testing for CKD in patients outside of the age range (patients under 18 years and those over 75 years of age). This measure assesses performance of a comprehensive kidney evaluation in adults aged 18-75. Patients with a diagnosis of ESRD Patients with a diagnosis of CKD Stage 5 Patients who have an order for or are receiving hospice or palliative care Patients who received a kidney health evaluation defined by an eGFR AND uACR within the measurement period ![]() ![]() Percentage of patients aged 18-75 years with a diagnosis of diabetes who received a kidney health evaluation defined by an Estimated Glomerular Filtration Rate (eGFR) AND Urine Albumin-Creatinine Ratio (uACR) within the measurement periodĪll patients aged 18-75 years with a diagnosis of diabetes at the start of the measurement period with a visit during the measurement period
0 Comments
Leave a Reply. |